KINDRED BIOSCIENCES, INC. (NASDAQ:KIN) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01Entry into a Material Definitive Agreement.

On March 29, 2018, Kindred Biosciences, Inc. (the “Company”) entered into a Standard Form of Agreement Between Owner and Design-Builder based upon AIA Document A141 – 2014 (the “Agreement”), with CRB Builders, LLC (“CRB”) in connection with the renovation of the Company’s manufacturing facility in Elwood, Kansas (the “Facility”).

to the Agreement, CRB will provide pre-construction and construction services in connection with constructing and renovating the Facility to provide approximately 16,500 square feet of new production space, and supporting Fill and Finish and Bio Production processes (the “Project”). The date for substantial completion of CRB’s work on the Project is set as February 22, 2019, which is subject to adjustment in accordance with the terms of the Agreement as the renovation progresses, or as agreed and requested by the Company. The Agreement is subject to customary undertakings, covenants, obligations, rights and conditions.

The foregoing summary of the material terms of the Agreement does not purport to be a complete description of the terms and provisions of the Agreement. The full text Agreement will be filed as an exhibit to our Quarterly Report on Form 10-Q for the quarter ending March 31, 2018, portions of which will be subject to a FOIA confidential treatment request to the Securities and Exchange Commission to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

Item 1.01. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 2, 2018, the board of directors (the “Board”) of the Company appointed Ernest Mario, Ph.D. to serve as a Class I director of the Company, effective as of April 2, 2018, for a term expiring at 2020 annual meeting of stockholders. As a result of Dr. Mario's appointment, the authorized size of the Board was increased to five members. There is no arrangement or understanding between Dr. Mario and any other person to which Dr. Mario was selected as a director. There are no relationships between Dr. Mario and the Company that would require disclosure to Item 404(a) of Regulation S-K. Dr. Mario is an independent director in accordance with the listing requirements of The NASDAQ Stock Market. Dr. Mario’s compensation will be consistent with the compensation of the Company’s other non-employee directors, and the Board will determine subsequently whether Dr. Mario will serve on any Board committees.

Dr. Mario previously served as a member of the Company's Board from February15, 2013 until May 23, 2016. Dr.Mario served as Deputy Chairman of Glaxo Holdings plc from 1992 to 1993 and as Chief Executive Officer from 1989 to 1993. From 1993 until 2001, he was Chairman and Chief Executive Officer of ALZA Corporation, a drug delivery technology company acquired by Johnson& Johnson in 2001. From 2003 until 2007, Dr.Mario served as Chairman and Chief Executive Officer of Reliant Pharmaceuticals, which was acquired by GlaxoSmithKline. He currently is Chairman of Soleno Therapeutics Inc., a public pharmaceutical company developing novel therapeutic products to treat migraine and allergic rhinitis. He is also a Venture Partner with Pappas Ventures and serves on a number of corporate boards, including the following public companies: Soleno Therapeutics Inc., Celgene Corporation, Chimerix Inc., Eyenovia Inc. and Tonix Pharmaceuticals Holding Corporation. Dr.Mario earned a B.S. in pharmacy at Rutgers University and his M.S. and Ph.D. in physical sciences at the University of Rhode Island. He holds honorary doctorates from the University of Rhode Island and Rutgers University. In 2007 he was awarded the Remington Medal by the American Pharmacists’ Association, pharmacy’s highest honor.

About KINDRED BIOSCIENCES, INC. (NASDAQ:KIN)

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company’s lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company’s other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.